Cervical Cancer
Conditions
Keywords
Cervical Cancer, Positron Emission Tomography, Fluorodeoxyglucose
Brief summary
Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer The purpose of this study is to evaluate the change in cervical tumor heterogenity as measured by FDG-PET/CT imaging.
Interventions
PROCEDUREPositron Emission Tomography
FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Biopsy-proven cervical cancer. (FIGO stage-Ib2-IVa) 2. Age ≥ 18 3. Able to receive chemoradiation therapy with Cisplatin. 4. Non-pregnant status in women of childbearing potential. 5. No other active cancer at the time of diagnosis of cervical cancer Patients cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years. 6. Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least 1 year. 7. Scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging of cervical cancer at Barnes-Jewish Hospital Clinical PET Facility on a Biograph 40 PET/CT scanner 8. Able to give informed consent
Exclusion criteria
1. Age \< 18 2. Patients with a known active malignancy other than cervical carcinoma. 3. Pregnant and breastfeeding patients. 4. Subjects whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overall goal of this pilot study is to evaluate the change in cervical tumor FDG heterogeneity and SUVmax during chemoradiation. | FDG PET/CT imaging is performed at: Baseline, 2 & 4 weeks of therapy, and 3 months after completing therapy |
Secondary
| Measure | Time frame |
|---|---|
| To correlate changed in FDG heterogeneity and SUVmax with response to therapy. | 5 years |
Countries
United States
Outcome results
None listed